

ASX ANNOUNCEMENT:

Update on 2020 Annual Meeting of Stockholders

26 March 2020 – Melbourne, Australia and Minnesota, United States – Osprey Medical (ASX:OSP) today advises that further to its announcement on 6 February 2020, due to the impact of COVID-19 and the health measures in place in Australia and the United States to limit its spread, its 2020 Annual Meeting of Stockholders will be held via webcast on Wednesday, 13 May 2020 at 9.00am Australian Eastern Standard Time (Tuesday, 12 May 2020 at 6.00pm U.S. Central Time) rather than at the Sydney office of Johnson Winter & Slattery, as previously advised.

Investors will be advised of further details regarding the 2020 Annual Meeting in a separate Notice of Meeting, which will be provided to investors closer to the date of the meeting. The Notice of Meeting will also be available on the ASX Market Announcements Platform and the Company's website (www.ospreymed.com).

Brendan Case
Australian Secretary

About Osprey Medical (ASX: OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Foreign Ownership Restriction

Osprey's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.